A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.

NCT Number	NCT05509153
Lead Sponsor	Western Sydney Local Health District Collaborators: Deakin University, Monash University, Royal Perth Hospital, The University of Queensland, University of Melbourne
Conditions	Huntington Disease
Enrollment	160 participants
Start Date	2024-06-01
Primary Completion	2026-11-01 (estimated)
Study Completion	2027-05-01 (estimated)
Updated on ClinicalTrials.gov	2025-02-28